DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
CLPT logo

ClearPoint Neuro, Inc. Stock Price

NasdaqCM:CLPT Community·US$428.6m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 24 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CLPT Share Price Performance

US$13.88
3.35 (31.81%)
​
US$23.50
Fair Value
US$13.88
3.35 (31.81%)
40.9% undervalued intrinsic discount
US$23.50
Fair Value
Price US$13.88
AnalystConsensusTarget US$23.50
AnalystLowTarget US$22.00
AnalystHighTarget US$30.00
Thu, 3 Sep 26
Fair ValueUS$23.50
Share Pricen/a

CLPT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$23.5 40.9% undervalued intrinsic discount

Minimally Invasive Neurosurgery Will Improve Global Clinical Outcomes

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$22 36.9% undervalued intrinsic discount

Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$30 53.7% undervalued intrinsic discount

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CLPT logo
ClearPoint Neuro
40.9% undervalued intrinsic discount

Minimally Invasive Neurosurgery Will Improve Global Clinical Outcomes

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative
CLPT logo
ClearPoint Neuro
36.9% undervalued intrinsic discount

Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 5 Aug
Read Narrative
CLPT logo
ClearPoint Neuro
53.7% undervalued intrinsic discount

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 6 Mar
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
CLPT logo

CLPT: Huntington’s Disease Partner Procedures Will Support Long Term Intracranial Upside

Fair Value: US$23.5 40.9% undervalued intrinsic discount
16 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
CLPT logo

CLPT: Huntington’s FDA Path And High ROI Focus Will Support Future Upside

Fair Value: US$22 36.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
CLPT logo

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

Fair Value: US$30 53.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Low risk with concerning outlook.

3 Risks
1 Reward
View Full Analysis

ClearPoint Neuro, Inc. Key Details

US$42.3m

Revenue

US$15.8m

Cost of Revenue

US$26.5m

Gross Profit

US$61.0m

Other Expenses

-US$34.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.13
62.61%
-81.76%
466.1%
View Full Analysis

About CLPT

Founded
1998
Employees
172
CEO
Joseph Burnett
WebsiteView website
www.clearpointneuro.com

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Recent CLPT News & Updates

User avatar
Narrative Update • Sep 03

CLPT: Huntington’s Disease Partner Procedures Will Support Long Term Intracranial Upside

Analysts have trimmed their average price target for ClearPoint Neuro from about $28.33 to $23.50 as they factor in updated targets from Lake Street and Stifel, along with expectations that management's higher ROI investment choices may affect near term growth, while they still see potential support from partner driven opportunities. Analyst Commentary Recent Street research on ClearPoint Neuro reflects a mix of optimism about long term growth potential and caution about the trade off between investment and near term execution.
Analysis Article • Aug 06

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates

ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) missed earnings with its latest second-quarter results, disappointing...
User avatar
Narrative Update • Aug 05

CLPT: Huntington’s FDA Path And High ROI Focus Will Support Future Upside

Analysts have trimmed the consolidated price target for ClearPoint Neuro to $22 from $25, reflecting slightly lower modeled revenue growth and profit margins as management focuses on higher ROI projects. These initiatives could weigh on near term results but are still seen as supported by potential partner driven catalysts.

Recent updates

No updates

ClearPoint Neuro, Inc. Competitors

IART logo

Integra LifeSciences Holdings

Symbol: NasdaqGS:IART
Market cap: US$1.3b
AORT logo

Artivion

Symbol: NYSE:AORT
Market cap: US$1.2b
PRCT logo

PROCEPT BioRobotics

Symbol: NasdaqGM:PRCT
Market cap: US$1.2b
STAA logo

STAAR Surgical

Symbol: NasdaqGM:STAA
Market cap: US$1.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide